PTEN and neoplasm: In PTEN-deficient cancers, AKT activation-induced GSK3β suppression results in the disruption of CHD1 proteolysis and aberrant accumulation of the CHD1 protein (25–27), which contributes to tumor development and tumor microenvironment (TME) remodeling.